Dr. Bence joined Pfizer’s Internal Medicine Research Unit in 2015, where she currently leads research and discovery efforts in the NASH and Obesity therapeutic areas. She leads a talented team of ~40 scientists focused on developing a deep understanding of the biological mechanisms underlying metabolic dysfunction and fatty liver disease, with the goal of identifying novel ways to treat and eventually prevent these metabolic diseases. She is also the Internal Medicine representative to the Pfizer WRD Post-Doctoral Program and has a strong commitment to training and mentoring the next generation of scientists. Dr. Bence received her B.A. in Biology from Colgate University, and her Ph.D. in Physiology and Biophysics from the Weill Cornell Medical College of Cornell University. She conducted her post-doctoral work at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, where she became interested in the role of cellular signaling in the regulation of metabolism. In 2006, Dr. Bence joined the University of Pennsylvania as an Assistant Professor and was subsequently promoted to Associate Professor with tenure.
